利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.018 秒)

    Sugar alcohol-based compositions for delivering nucleic acid-based drugs in vivo and in vitro
    1.
    发明授权
    Sugar alcohol-based compositions for delivering nucleic acid-based drugs in vivo and in vitro 有权
    用于在体内和体外递送基于核酸的药物的基于糖醇的组合物

    公开(公告)号：US09387251B2

    公开(公告)日：2016-07-12

    申请号：US14457829

    申请日：2014-08-12

    申请人： Shi-Lung Lin ,  David T S Wu

    发明人： Shi-Lung Lin ,  Yi-Wen Lin

    IPC分类号： A61K47/26 ,  A61K31/713 ,  A61K31/7105 ,  C12N15/11 ,  C12N15/113

    CPC分类号： A61K47/26 ,  A61K31/7105 ,  A61K31/713 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/141 ,  C12N2320/32 ,  C12N2330/50 ,  C12N2330/51 ,  C12N2740/15041

    摘要： This invention relates to a composition and its use for formulating nucleic acid-based drugs/vaccines with sugar alcohol compositions into complexes for both in-vitro and in-vivo delivery. Particularly, the present invention includes the ingredients and processes necessary for formulating therapeutic and pharmaceutical nucleic acid compositions, such as miRNA, microRNA precursors, shRNAs, siRNAs, ribozymes, antisense RNAs/DNAs, RNA-DNA hybrids and DNA vectors/vaccines, with glycylated sugar alcohols/sugars into delivery complexes, which can then be absorbed by cells in vivo and in vitro via active endocytosis. Also, the present invention discloses that chemical compounds containing sugar alcohol- and/or sugar-like structures can protect nucleic acids, in particular miRNAs, shRNAs, siRNAs and ribozymes, from degradation in vivo as well as in vitro. Therefore, the present invention is also a formula and method for preserving the structural integrity and functional efficacy of these nucleic acid-based drugs and/or vaccines in vivo and in vitro.

    摘要翻译： 本发明涉及一种组合物及其用于将糖醇组合物配制成用于体外和体内递送的复合物的基于核酸的药物/疫苗的用途。 特别地，本发明包括配制具有糖基化的治疗和药物核酸组合物如miRNA，微RNA前体，shRNA，siRNA，核酶，反义RNA / DNA，RNA-DNA杂交体和DNA载体/疫苗所必需的成分和方法 糖醇/糖进入递送复合物，其然后可以通过活性内吞作用在体内和体外被细胞吸收。 此外，本发明公开了含有糖醇和/或糖类结构的化合物可以保护核酸，特别是miRNA，shRNA，siRNA和核酶免受体内和体外降解。 因此，本发明也是用于在体内和体外保持这些基于核酸的药物和/或疫苗的结构完整性和功能功效的配方和方法。

    Use of Novel Monosaccharide-like Glycylated Sugar Alcohol Compositions for Designing and Developing Anti-Diabetic Drugs
    2.
    发明申请
    Use of Novel Monosaccharide-like Glycylated Sugar Alcohol Compositions for Designing and Developing Anti-Diabetic Drugs 有权
    使用新型单糖样糖基化糖醇组合物设计和开发抗糖尿病药物

    公开(公告)号：US20150209377A1

    公开(公告)日：2015-07-30

    申请号：US14585978

    申请日：2014-12-30

    申请人： Shi-Lung Lin ,  Samantha Chang-Lin ,  Yi-Wen Lin ,  Donald Chang

    发明人： Shi-Lung Lin ,  Samantha Chang-Lin ,  Yi-Wen Lin ,  Donald Chang

    IPC分类号： A61K31/7012 ,  A61K31/221

    CPC分类号： A61K31/221 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/7012 ,  A61K31/7024 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/141 ,  C12N2320/32 ,  C12N2330/50 ,  C12N2330/51

    摘要： This invention is related to a novel sugar-like chemical composition and its use for diabetes therapy. Particularly, the present invention teaches the use of monosaccharide-like glycylated sugar alcohol compounds to block or reduce sugar absorption in diabetes patients, so as to prevent the risk of hyperglycemia symptoms. Glycylation of sugar alcohols is a totally novel reaction that has never been reported before. Therefore, the novelty of the present invention is that for the first time glycylated sugar alcohols not only was found but also was found to be useful for treating Diabetes mellitus. In addition, the present invention teaches a method for producing these glycylated sugar alcohols. In sum, the present invention includes not only a kind of novel sugar-like chemical compositions and its use for treating diabetes but also a state-of-the-art protocol and methodology for producing such a novel composition via glycylation of sugars and sugar alcohols.

    摘要翻译： 本发明涉及新型糖类化学组合物及其用于糖尿病治疗的用途。 特别地，本发明教导了使用单糖样的糖化糖醇化合物来阻止或减少糖尿病患者的糖吸收，以防止高血糖症状的风险。 糖醇的糖基化是一种完全新颖的反应，从未在之前报道过。 因此，本发明的新颖性不仅首次发现了糖化糖醇，而且被发现可用于治疗糖尿病。 此外，本发明教导了一种制备这些糖基化糖醇的方法。 总之，本发明不仅包括一种新型的糖类化学组合物及其用于治疗糖尿病的用途，而且还包括通过糖和糖醇的糖基化制备这种新型组合物的最新方案和方法 。